Insider Bazemore Buys 13,100 ADS in AKARI THERAPEUTICS Amid 73% YoY Loss and Negative P/E—Confidence Amid Crisis?

Insider Activity Highlights for AKARI THERAPEUTICS

The latest Form 4 filing from Robert B. Bazemore shows a sizeable purchase of 13,100 American Depositary Shares (ADS) at $7.90 per share, increasing his holdings to 14,216. This trade coincides with a broader wave of insider buying across the board – the company’s top executives and directors have collectively added more than 70 k shares in the past month. The volume is notable because it follows a sharp 6.7 % weekly decline and a 19.2 % monthly slide in the stock, suggesting that insiders still see upside potential even as market sentiment has turned negative (the company’s price‑earnings ratio is now a negative –0.022).

What It Means for Investors

For long‑term investors, the continued accumulation by senior management can be interpreted as a vote of confidence. Bazemore’s purchase is part of a pattern of RSU grants and options that vest once shareholder approval is obtained, aligning his incentives with the company’s long‑term success. However, the stock’s steep year‑to‑date loss of over 73 % and the 52‑week high of $33.60 illustrate the volatility that investors face. The high buzz score (494 %) and positive sentiment (+83) in social‑media chatter suggest that news of insider buying is generating excitement, but the negative price trend could still outweigh that sentiment in the short run.

Bazemore’s Insider Profile

Bazemore has a history of buying large warrant and option blocks, as seen in December 2025 when he acquired over 150 k ADR warrants and pre‑funded warrants at $0.40 each. His recent transactions—RSUs and ADS purchases—follow the same “reward‑for‑performance” model. He has also sold pre‑funded warrants in October 2026, a move that indicates a willingness to monetize future upside once shareholder approval is secured. Overall, Bazemore’s activity is aggressive yet structured, with a focus on long‑term equity exposure rather than short‑term speculation.

Strategic Takeaway

Insider buying in a company that is still in a steep decline can be a double‑edged sword. On the one hand, it signals that those closest to the day‑to‑day operations remain committed; on the other hand, the company’s fundamentals—negative earnings, low market cap, and a steep drop in share price—indicate that the upside may be far off. Investors should weigh Bazemore’s continued stake against the broader market context and consider whether the company’s pipeline and pipeline development in anti‑inflammatory therapeutics could justify a rebound in the long run.